Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Forte Biosciences Inc (FBRX)

Forte Biosciences Inc (FBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Forte Biosciences Announces Pricing of $150 Million Public Offering Business Wire - Wed Apr 8, 8:30PM CDT

Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares...

FBRX : 26.66 (-4.89%)
Forte Biosciences Announces Proposed Public Offering Business Wire - Wed Apr 8, 3:02PM CDT

Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering...

FBRX : 26.66 (-4.89%)
Forte Biosciences, Inc. Announces 2025 Results and Provides Update Business Wire - Tue Mar 31, 3:01PM CDT

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its full year...

FBRX : 26.66 (-4.89%)
Forte Biosciences Faces Critical Test as Losses Expected to Widen Sharply Barchart - Thu Mar 26, 4:01PM CDT

Barchart Research What to Expect from FBRX Earnings FBRX Generated March 26, 2026 Current Price $27.01 EPS Estimate $-1.42 Consensus Rating Strong Buy Average Move 6.02% Forte Biosciences Faces Critical...

FBRX : 26.66 (-4.89%)
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules Business Wire - Tue Mar 17, 3:01PM CDT

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody...

FBRX : 26.66 (-4.89%)
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules Business Wire - Wed Mar 4, 3:01PM CST

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody...

FBRX : 26.66 (-4.89%)
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings Business Wire - Mon Feb 9, 3:01PM CST

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be...

FBRX : 26.66 (-4.89%)
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules Business Wire - Mon Dec 22, 2025

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody...

FBRX : 26.66 (-4.89%)
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules Business Wire - Mon Nov 24, 2025

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody...

FBRX : 26.66 (-4.89%)
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update Business Wire - Fri Nov 14, 2025

Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata

FBRX : 26.66 (-4.89%)

Barchart Exclusives

A $20 Billion Reason to Buy Dividend-Paying Visa Stock Now Barchart - Thu Apr 30, 6:30PM CDT
Visa has released its second-quarter results while announcing a massive $20 billion share repurchase program. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.